elucid vivo logo

See Beyond the Lumen

Deliver personalized patient care with the only histologically-validated, objective and quantitative CTA-based arterial analysis software.

Utilize ground-truth histology to visualize the source of myocardial ischemia and inform heart attack and stroke risk.
Clinical Problem

Misdiagnosed Myocardial Ischemia, Heart Attack & Stroke Risk Leads to Poor Outcomes

Myocardial ischemia occurs when blood flow to your heart is reduced, preventing the heart muscle from receiving enough oxygen. This is often the result of plaque buildup inside the artery wall.

Heart attack and stroke are primarily caused by non-obstructive, but unstable plaque in the arteries that goes undiagnosed and untreated.1 Current non-invasive testing cannot visualize the biology deep inside artery walls where heart disease develops.

Elucid is harnessing scientific imaging and histology to help enable quick, accurate, noninvasive diagnoses and precise treatment of cardiovascular disease to enable better patient outcomes.

A man and woman hiking
elucid vivo logo

PlaqueIQ Technology

Accurate Clinical Insights Based on Biology

Introducing the first and only non-invasive image analysis software that employs CT angiography and patented computer algorithms, based on expert histologic examination of thousands of tissue samples and images, to objectively quantify the extent and stability of arterial plaque for tailored patient care.

Technology backed by 40+ years of clinical research

12 clinical studies and 70+ publications

Powerful. Precise. Proven.

Unprecedented accuracy authorized for use in all arteries.

Icon of human heart87%

Accurate prediction of major adverse cardiac events2*

Icon of human heart40%

Better Stroke Prediction3*

*Compared to current stenosis-based guidelines

ElucidVivo Comprehensive
Healthcare Solutions

  • Assess plaque composition with histology-validated software
  • Quantify plaque to inform heart attack and stroke risk with greater accuracy
  • Visualize a comprehensive and objective view of arterial disease to enable personalized treatment plans before a patient ever enters the hospital
  • Understand your risk of heart attack and stroke
  • Receive safe and accurate non-invasive diagnostic testing
  • Experience personalized treatment plans
  • Early detection for improved clinical care and consistent outcomes
  • Reduce unnecessary invasive testing, lowering cost of care
  • Enables physicians to identify asymptomatic high-risk patients who may have otherwise gone untreated
  • Help identify promising drug candidates with greater speed and accuracy
  • May reduce clinical trial size, costs and timelines by stratifying high-risk patients
  • If you are interested in submitting a proposal for a research study, click here.
PlaqueIQ Technology

Translate CTA into Scientific Images in 2 Steps

Accurately restore vessel structure and plaque morphology, including lipid rich necrotic core:

High-Fidelity Patented
Image Processing
Complete 3D Plaque Visibility and Analysis
Complete 3D Plaque Visibility and Analysis

The only CTA-based plaque assessment rigorously validated with histopathology*

Based on expert analysis of microscopic tissue samples by world-renowned cardiovascular pathologists.

*Available in ElucidVivo Research Edition only.
In partnership with:
CV Path Institute
LSU Health New Orleans
The ElucidVivo algorithms demonstrate excellent correlation and are highly accurate for tissue characterization when compared to ex vivo histopathology.”
Renu Virmani, MD

President & Medical Director at CVPath Institute

Secure, Workflow-Oriented Technology

Icon of Patient in Hospital
Works with all CTA scanners using standard acquisition protocols.
Icon of Laptop
Accessed via secure, locally deployed software or cloud-based analysis designed to protect sensitive patient data transmission to and from hospital IT systems.
Icon of iPad and Doctor
Integrates seamlessly into EMR, PACS, and imaging workflow for accurate and timely clinical decision-making.

Elucid Names Kelly Huang as CEO

Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis software BOSTON, July 22, 2024 – Elucid, a pioneering AI medical technology company providing physicians with imaging...

read more

Bringing Imaging to Life

Our mission is to provide comprehensive and accurate clinical insights based on ground-truth histology, enabling unprecedented precision healthcare for vascular disease. Contact us today to learn more about ElucidVivo clinical solutions:

Our Portfolio

ElucidVivo PlaqueIQ

FDA-cleared, non-invasive CTA analysis software providing unprecedented specificity of plaque stability and vessel structure, based on histology.

ElucidVivo FFRCT + PlaqueIQ

Combination of plaque analysis, based on histology, and FFR for a more direct measure of stress induced ischemia while characterizing plaque risk. Coming Soon!

ElucidVivo Clinical Research

CTA analysis software with innovative additional features for clinical research and studies.

ElucidVivo is used to help evaluate patient outcomes, safety and clinical efficacy in clinical trials with industry partners, including:


Medical University Southern California
National Institutes of Health
University of Maryland Medical System

Contact us today to learn more about ElucidVivo or to schedule a product demo.


399 Boylston Street, Suite 400
Boston, MA 02116
*Compared to current stenosis-based guidelines 1. Stone, Gregg. PROSPECT II/PROSPECT ABSORB. TCT CONNECT 2020 Late Breaking Trial Session. 2. van Assen, M., et al., Automated plaque analysis for the prognostication of major adverse cardiac events. European Society of Radiology, 2019. 3. Lal B.K., et al. Novel Application of Artificial Intelligence Algorithms to Develop a Predictive Model for Major Adverse Neurologic Events in Patients With Carotid Atherosclerosis. Journal of Vascular Surgery. July 2020. DOI: 10.1016/j.jvs.2020.04.306. Compared to current stenosis based guidelines. 4. Elucid Technology FDA 510k summary – K183012; December 21, 2018.